



(51) International Patent Classification:

G01N 33/68 (2006.01) G01N 30/72 (2006.01)  
G01N 33/53 (2006.01) A61K 38/42 (2006.01)  
G01N 30/22 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2015/031996

(22) International Filing Date:

21 May 2015 (21.05.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/001,911 22 May 2014 (22.05.2014) US  
62/095,413 22 December 2014 (22.12.2014) US

(71) Applicants (for all designated States except US): UNIVERSITY OF MARYLAND, BALTIMORE [US/US]; 620 W. Lexington Street, 4th floor, Baltimore, Maryland 21201 (US). RAMOT AT TEL-AVIV UNIVERSITY LTD. [IL/IL]; P.O. Box 39296, 6139201 Tel Aviv (IL).

(72) Inventors; and

(71) Applicants (for US only): LU, Wuyuan [US/US]; 9914 Frederick Road, Ellicott City, Maryland 21042 (US). WITZ, Isaac [IL/IL]; 18 Aharon Box Street, 74067 Ness Ziona (IL). MAMAN, Shelly [IL/IL]; 1 Eli Cohen Street, 69630 Tel Aviv (IL).

(74) Agent: HISSONG, Drew; Wenderoth, Lind & Ponack, LLP, 1030 15th Street NW, Suite 400 East, Washington, D.C. 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: TREATMENT OF CANCER AND INHIBITION OF METASTASIS USING HEMOGLOBIN BETA SUBUNIT

Figure 6



(57) Abstract: The beta 2 subunit of mouse hemoglobin (HBB2) has been identified as soluble factor from mouse lungs that exhibits cytostatic/cytotoxic activity against neuroblastoma lung micrometastases. The beta subunit of human hemoglobin (HBB) has been found to have similar activity. Methods of using these proteins and fragments thereof in the treatment of cancer and inhibition of metastasis are provided, along with methods of screening a subject for micrometastases by detecting HBB in a biological sample.

WO 2015/179657 A1

— *with sequence listing part of description (Rule 5.2(a))*

## TREATMENT OF CANCER AND INHIBITION OF METASTASIS USING HEMOGLOBIN BETA SUBUNIT

### STATEMENT OF FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

[0001] This invention was made with government support under Grant No. AI072732 awarded by the National Institutes of Health. The government has certain rights in the invention.

### BACKGROUND OF THE INVENTION

[0002] Metastasis is the major cause of cancer-related deaths (Gupta et al., 2006). Metastatic disease may develop years or even decades after successful treatment of the primary tumor (Aguirre-Ghiso et al., 2007; Pantel et al., 2004). This prolonged latency phase occurring between treatment and disease progression is often due to tumor dormancy (Aguirre-Ghiso et al., 2007), a stage in which residual disease is present but not clinically apparent. Tumor dormancy is caused either by cell cycle arrest (Chambers et al., 2002; Townson et al., 2006) or by a balance between proliferation and cell death (Holmgren et al., 1995). Tumor progression to late relapse and frank metastasis is often due to the awakening of dormant micrometastases (Chambers et al., 2002; Pantel et al., 2007; Wikman et al., 2008).

[0003] The mechanisms that sustain dormancy and those regulating the transition from dormancy to progressive disease from micrometastases remain widely unknown (Aguirre-Ghiso et al., 2007). However, the microenvironment is thought to play a critical role in tumor growth and progression (Joyce et al., 2009; Kim et al., 2011; Witz et al., 2008; Witz et al., 2008; Witz et al., 2006) and accumulating evidence suggests that the mechanisms governing tumor dormancy and metastatic recurrence are largely regulated by the microenvironment of the distant organ in which micrometastases are present (Klein-Goldberg et al., 2014; Maman et al., 2013b; Paez et al., 2012; Wikman et al., 2008).

[0004] A notable example is neuroblastoma, the most common extracranial solid tumor in children. Despite intensive treatment regimens, 60% to 70% of children with high-risk disease will ultimately experience relapse due to the presence of neuroblastoma micrometastasis (Smith et al., 2010). Since cure after relapse of high-risk disease is extremely rare, it is a necessity to identify novel and reliable modalities for the inhibition and elimination of neuroblastoma micrometastases.

[0005] Using a xenotransplant system (Nevo et al., 2008), it was reported that human neuroblastoma cells inoculated orthotopically into the adrenal gland of nude mice migrate to

the lung and form dormant micrometastases (MicroNB) (Edry Botzer et al., 2011). These dormant micrometastases persist for long periods of time without forming overt metastasis. This situation is consistent with the observation that lung metastasis in neuroblastoma patients is a relatively late event in the progression of this disease (Cowie et al., 1997; Kammen et al., 2001). The state of dormancy of the micrometastatic cells is lung-specific: MicroNB cells harvested from lungs proliferated in culture and produced local tumors when inoculated into the adrenal gland of nude mice, indicating that once removed from the restraining lung microenvironment they were able to propagate (Edry Botzer et al., 2011).

**[0006]** Based on these findings, it was postulated that neuroblastoma lung metastases are regulated by the lung microenvironment. Specifically, it was hypothesized that the MicroNB cells residing in the lungs are dormant at this site because of proliferation-restraining functions of the lung microenvironment. This hypothesis was confirmed by a showing that lung-derived factors significantly reduced the viability of MicroNB cells by up-regulating the expression of pro-apoptotic genes, inducing cell cycle arrest, and decreasing ERK and FAK phosphorylation in these cells (Maman et al., 2013).

**[0007]** The identification of specific factors that maintain dormant micrometastases or that trigger active metastatic growth from micrometastases will be important in the development of new means for detecting the presence of micrometastases and for treating and/or preventing them. The present invention is directed to these and other important goals.

#### **BRIEF SUMMARY**

**[0008]** As described in detail below, the inventors of the present application found a soluble factor from normal mouse lungs that exhibits cytostatic/cytotoxic activity against neuroblastoma metastases and micrometastases to distant organs (such as lung, bone marrow, liver, and spleen), as well as several other cancers, such as breast, cervical, prostate, skin (melanoma) and lung carcinoma. The molecule was purified and identified as the beta 2 subunit of mouse hemoglobin (HBB2). Purified human hemoglobin beta subunit (HBB), which shares 80% sequence identity to mouse HBB2, was found to have a comparable cytostatic/cytotoxic effect on neuroblastoma cells, whereas the alpha subunit of human hemoglobin was inactive.

**[0009]** The inhibitory activity of HBB was found in the carboxy-terminal part of the protein in a specific amino acid sequence (ENFRLLGNVLVCVLA, termed HBB11p; SEQ ID NO:5). Treatment with this short inhibitory peptide significantly inhibited local

neuroblastoma tumor growth, and both lung and bone marrow metastasis, indicating its potential to serve as a new anticancer drug.

**[0010]** HBB2 expression is significantly elevated in the serum and organs of mice harboring neuroblastoma micrometastases, indicating that HBB can serve as a biomarker for predicting tumor progression.

**[0011]** Thus, and in a first aspect, the present invention is directed to methods of screening a subject for micrometastases comprising (a) obtaining a biological sample from a subject, (b) determining the amount of an HBB peptide in the sample, and (c) comparing to amount determined in (b) with a reference amount.

**[0012]** In one particular aspect, when the amount determined in (b) is more than the reference amount, the subject is diagnosed as having micrometastases. In another particular aspect, when the amount determined in (b) is the same as or less than the reference amount, the subject is diagnosed as being free of micrometastases.

**[0013]** In this first aspect, the biological sample may be, but is not limited to, blood, serum and sputum.

**[0014]** In this first aspect, the HBB peptide may be, but is not limited to, HBB (i.e., human hemoglobin beta subunit).

**[0015]** In this first aspect, the amount of an HBB peptide in the biological sample may be determined by means that include, but are not limited to, western blot, dot blot, slot blot, ELISA, RP-HPLC, LC-MS and LC-MS/MS.

**[0016]** In this first aspect, the micrometastases may be, but are not limited to, breast, cervical, prostate, kidney, lung, skin, ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, or cancer of the nervous system, in origin. In particular, the micrometastases may be neuroblastomal (cancer of the nervous system) in origin.

**[0017]** In a second aspect, the present invention is directed to methods of treating a subject having cancer comprising administering an effective amount of an HBB peptide to a subject having cancer.

**[0018]** The cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma.

**[0019]** In a non-limiting example, the method is one of treating a subject having neuroblastoma comprising administering an effective amount of an HBB peptide to a subject having neuroblastoma.

[0020] In a third aspect, the present invention is directed to methods of inhibiting development of cancer in a subject at risk of developing cancer comprising administering an effective amount of an HBB peptide to a subject at risk of developing cancer.

[0021] The subject at risk of developing cancer may be a subject that was previously treated for cancer or neuroblastoma. The subject at risk of developing cancer may be a subject in which cancer or neuroblastoma was previously cured.

[0022] The cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma.

[0023] In a non-limiting example, the method is one inhibiting development of neuroblastoma in a subject at risk of developing neuroblastoma comprising administering an effective amount of an HBB peptide to a subject at risk of developing neuroblastoma.

[0024] In a fourth aspect, the present invention is directed to methods of inhibiting metastasis of cancer in a subject having cancer comprising administering an effective amount of an HBB peptide to a subject having cancer.

[0025] The cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma.

[0026] In a non-limiting example, the method is one inhibiting metastasis of neuroblastoma in a subject having neuroblastoma comprising administering an effective amount of an HBB peptide to a subject having neuroblastoma.

[0027] In a fifth aspect, the present invention is directed to pharmaceutical compositions comprising one or more HBB peptides and a pharmaceutically acceptable carrier.

[0028] In relevant aspects of the invention, the HBB peptide is one that is selected from the group consisting of (a) mouse HBB2, (b) human HBB, (c) a peptide comprising HBB11p (SEQ ID NO:5), (d) a peptide consisting of HBB11p, e) a variant of any one of (a) through (d) having 10 or fewer amino acid changes, and (f) functional derivatives of (a) through (e).

[0029] In relevant aspects of the invention, the HBB peptide may be administered to the subject as a pharmaceutical composition comprising an HBB peptide and a carrier.

[0030] In a sixth aspect, the present invention is directed to the use of an HBB peptide in a method of treating a subject having cancer. In a non-limiting example, an effective amount of an HBB peptide is administered to a subject having cancer.

**[0031]** The cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma.

**[0032]** In a non-limiting example, the HBB peptide is used in a method of treating a subject having neuroblastoma, wherein an effective amount of an HBB peptide is administered to a subject having neuroblastoma.

**[0033]** In a seventh aspect, the present invention is directed to the use of an HBB peptide in a method of inhibiting development of cancer in a subject at risk of developing cancer. In a non-limiting example, an effective amount of an HBB peptide is administered to a subject at risk of developing cancer.

**[0034]** The subject at risk of developing cancer may be a subject that was previously treated for cancer or neuroblastoma. The subject at risk of developing cancer may be a subject in which cancer or neuroblastoma was previously cured.

**[0035]** The cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma.

**[0036]** In a non-limiting example, the HBB peptide is used in a method of inhibiting development of neuroblastoma in a subject at risk of developing neuroblastoma, wherein an effective amount of an HBB peptide is administered to a subject at risk of developing neuroblastoma.

**[0037]** In an eighth aspect, the present invention is directed to use of an HBB peptide in a method of inhibiting metastasis of cancer in a subject having cancer. In a non-limiting example, an effective amount of an HBB peptide is administered to a subject having cancer.

**[0038]** The cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma.

**[0039]** In a non-limiting example, the HBB peptide is used in a method of inhibiting metastasis of neuroblastoma in a subject having neuroblastoma, wherein an effective amount of an HBB peptide is administered to a subject having neuroblastoma.

**[0040]** In a ninth aspect, the present invention is directed to the use of an HBB peptide for the manufacture of a medicament for treating cancer in a subject. The cancer may be one or more

of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma. In a non-limiting example, the HBB peptide is used for the manufacture of a medicament for treating neuroblastoma in a subject.

**[0041]** In a tenth aspect, the present invention is directed to the use of an HBB peptide for the manufacture of a medicament for inhibiting development of cancer in a subject at risk of developing cancer. The cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma. In a non-limiting example, the HBB peptide is used for the manufacture of a medicament for inhibiting development of neuroblastoma in a subject at risk of developing neuroblastoma.

**[0042]** In an eleventh aspect, the present invention is directed to the use of an HBB peptide for the manufacture of a medicament for inhibiting metastasis of cancer in a subject having cancer. The cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma. In a non-limiting example, the HBB peptide is used for the manufacture of a medicament for inhibiting metastasis of cancer in a subject having cancer.

\*

\*

\*

\*

**[0043]** The foregoing has outlined rather broadly the features and technical advantages of the present invention in order that the detailed description of the invention that follows may be better understood. Additional features and advantages of the invention will be described herein, which form the subject of the claims of the invention. It should be appreciated by those skilled in the art that any conception and specific embodiment disclosed herein may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present invention. It should also be realized by those skilled in the art that such equivalent constructions do not depart from the spirit and scope of the invention as set forth in the appended claims. The novel features which are believed to be characteristic of the invention, both as to its organization and method of operation, together with further objects and advantages will be better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood,

however, that any description, figure, example, etc. is provided for the purpose of illustration and description only and is by no means intended to define the limits the invention.

#### **BRIEF DESCRIPTION OF DRAWINGS**

**[0044] Figures 1A-1E.** Isolation of an inhibitory lung factor. **Fig. 1A:** Normal mouse lungs (ConLung) were harvested, minced and filtered, and soluble factors were collected. **Fig. 1B:** MTS-based viability assay indicated that dialyzed (3500 MW Da cutoff) lung-derived factors inhibited cell viability to the same extent as non-dialyzed lung-derived factors. **Fig. 1C:** HPLC separation of dialyzed lung-derived factors resulted in 4 distinctive peaks. **Fig. 1D:** MTS-based viability assay revealed that peak no. 4 inhibited cell viability. **Fig. 1E:** HPLC purification of peak no. 4 resulted in one peak. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.005$ .

**[0045] Figures 2A-2C.** Identification of the isolated inhibitory lung factor. **Fig 2A:** Mass spec analysis of the HPLC-separated peak no. 4 indicated that the peak harbored a single protein of a MW of 15824.5 Da. **Fig 2B:** Sequence analysis by LC-MS/MS coupled with tryptic digestion of the inhibitory peak no. 4 revealed a 147 amino acid sequence (SEQ ID NO:1). Database search in the International Protein Index (IPI) revealed a 100% identity to the mouse beta subunit of hemoglobin (HBB2). **Fig 2C:** HBB2 was verified as the inhibitory lung factor when the addition of a specific anti-mouse HBB2 antibody blocked the inhibitory activity of lung-derived factors incubated with MicroNB and MacroNB cells.\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.005$ .

**[0046] Figures 3A-3E.** Isolation and characterization of human HBB. **Fig. 3A:** HPLC separation of native human hemoglobin resulted in the isolation of the beta subunit of a MW of 15867 Da. **Fig. 3B:** Structure prediction of human HBB by I-TASSER tool revealed a helical structure. **Fig. 3C:** Circular dichroism analysis of human hemoglobin (HB), hemoglobin subunit alpha (HBA) and subunit beta (HBB) indicated a helical structure for all three proteins. **Fig. 3D:** MTS-based viability assay indicated that human HBB inhibits the viability of MicroNB and MacroNB cells. HBA did not influence cell viability. **Fig. 3E:** MTS-based viability assay indicated that human HBB inhibits the viability of MCF-7 breast carcinoma cells as well. The whole human hemoglobin protein inhibited cell viability as well but not to the same extent as HBB. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.005$ , \*\*\*\* $p < 0.001$ .

**[0047] Figures 4A-4C.** Human HBB inhibits the viability of neuroblastoma cells by a G0-G1 cell cycle arrest. Human HBB2 (1 $\mu$ g) was incubated with MicroNB and MacroNB cells for 48 hr. **Fig. 4A:** Whole cell lysates of MicroNB and MacroNB cells incubated with human HBB were subjected to western blot analysis and immunostaining. ERK1/2 phosphorylation

was calculated in reference to total ERK2, as measured by densitometry. **Fig. 4B:** Cell-cycle analysis was performed using flow cytometry to examine the percentage of cells in G0-G1 phase. **Fig. 4C:** Whole cell lysates of MicroNB and MacroNB cells incubated with human HBB were subjected to western blot analysis and immunostaining. Cyclin D1 expression was calculated in reference to beta-tubulin. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.005$ , \*\*\*\* $p < 0.001$ .

**[0048] Figures 5A-5C.** Pin-pointing the active inhibitory fragment of human HBB. **Fig. 5A:** Cleavage of human HBB protein after the amino acid methionine using CNBr resulted in N- and C-terminal fragments (SEQ ID NOs:3 and 4). **Fig. 5B:** MTS-viability assay revealed that most of the inhibitory activity of human HBB is in the C-terminal part of the protein. **Fig. 5C:** MTS-based viability assay indicated that peptide 11 of human HBB inhibited the viability of MicroNB cells to a greater extent than human HBB. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.005$ .

**[0049] Figures 6A-6D.** HBB2 expression is elevated in mice harboring micrometastasis. Sixteen mice were orthotopically inoculated to the adrenal gland with either neuroblastoma micrometastases or PBS (normal mice). After 8 weeks, lungs, liver and bone marrow were harvested from the mice and blood was collected (**Fig. 6A**). Mice organs were examined for the presence of human neuroblastoma cells using real time PCR and for mHBB2 expression using western blot analysis (**Fig. 6B**, **Fig. 6C**) and immunostaining of frozen sections (**Fig. 6D**).

**[0050] Figures 7A-7E.** Treatment with HBB11p inhibits local tumor growth and lung metastasis. Twenty four mice were orthotopically inoculated to the adrenal gland with neuroblastoma micrometastases. Two weeks post inoculation, mice were either i.v. injected with HBB11p or forced to inhale a droplet of soluble HBB11p, once a week for 8 weeks (**Fig. 8A**). Mice were monitored weekly for tumor volume (**Fig. 8B**). At the end of the experiment, local tumors were weighed (**Fig. 8C**) and organs were harvested and examined for the presence of human neuroblastoma cells (**Fig. 8D**) and for the expression of mHBB2 (**Fig. 8E**) using real time PCR.

**[0051] Figures 8A-8F.** A short fragment of human HBB (Metox) inhibits neuroblastoma local tumor growth and metastasis. **Fig. 8A:** Mice were orthotopically inoculated to the adrenal gland with neuroblastoma micrometastases. Fourteen days post inoculation, mice were intranasally treated with HBB11p ("Metox") or with a scrambled Metox peptide (control group), once a week for 8 weeks. Mice were monitored weekly for tumor volume. At the end of the experiment, local tumors were weighed and organs were harvested and examined for the presence of human neuroblastoma cells and for mHBB2 expression using

real time PCR. **Fig. 8B:** Volume measurements of local tumors of mice treated with Metox or scrambled-Metox. **Fig. 8C:** Mice treated with Metox or scrambled-Metox were photographed right before the extraction of local adrenal tumors. Local adrenal tumors were photographed as well. **Fig. 8D:** Local adrenal tumors were weighed right after extraction from mice. **Fig. 8E:** Real time PCR quantification of MicroNB cells in mouse lungs. **Fig. 8F:** Real time PCR quantification of MicroNB cells in mouse bone marrow. Data are means of mice in each group (n=24, 12 mice in each group)  $\pm$ SD. Significance was evaluated using Student's t-test. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.005, \*\*\*\*p < 0.001.

## DETAILED DESCRIPTION

**[0052]** The hypothesis underlying the present invention is that factors from the lung microenvironment restrain the proliferation of micrometastases from neuroblastoma and other cancers, thus inhibiting progression towards overt metastasis. In a previous study (Maman et al., 2013), the inventors demonstrated that indeed the microenvironment of the normal lung possesses the capacity to do so. Factors derived from normal mouse lungs significantly inhibited the viability of MicroNB cells, up-regulated apoptosis and down-regulated cell cycle progression genes, induced cell cycle arrest and apoptosis, up-regulated the expression of stem cell markers and decreased ERK and FAK phosphorylation in these cells. This microenvironment-mediated regulation of neuroblastoma cell viability supported the hypothesis that factors in the lung microenvironment kept the micrometastatic tumor cells in a state of dormancy and inhibited their propagation thereby preventing overt lung metastasis.

**[0053]** As reported herein, the inventors have now isolated a soluble factor from normal mouse lungs that exhibits cytostatic/cytotoxic activity against neuroblastoma lung metastases and micrometastases, namely the beta 2 subunit of mouse hemoglobin (HBB2). Along with its human counterpart (HBB), these hemoglobin beta subunits can be employed as anticancer drugs either alone or in combination with other drugs and/or cancer treatments. For example, an HBB peptide can be used alone or with other drugs to treat primary tumors, inhibit developments and/or growth of primary tumors, to treat minimal residual disease in cancer patients (e.g., in conjunction with surgery, chemotherapy, and/or radiation therapy), and/or to inhibit or block development and progression of metastatic cancer. HBB peptides can be derivatized to increase their half-life and/or bioavailability, and/or to improve their targeting to cancerous tissue.

**[0054]** Truncation studies on the beta chain of human hemoglobin (HBB) identified the amino acid sequence ENFRLLGNVLCVLA (HBB11p; SEQ ID NO:5) as containing the anti-tumor/anti-metastatic activity of the larger protein, both *in vivo* and *in vitro*. This peptide, also designated Metox, can be used as an anti-tumor drug.

**[0055]** The identification of endogenous HBB as a factor that inhibits micrometastatic neuroblastoma cells and perhaps other metastasizing cells indicates that the arsenal of innate resistance mechanisms may contain factors with unrelated physiological functions. Such endogenous factors may take part in regulated cancer recurrence and can be employed to develop novel therapies to treat and prevent cancer metastasis and for the treatment of residual disease.

**[0056]** Moreover, because the beta subunit of murine hemoglobin (HBB2) is expressed by lung cells and it is up-regulated in nude mice bearing human neuroblastoma xenografts, HBB2 and HBB can be used as biomarkers for disease.

#### HBB Peptides

**[0057]** For the sake of convenience, the proteins and peptides that may be used in the various aspects of the present invention are termed “HBB peptides” herein. The proteins and peptides include (a) the beta subunit of mouse hemoglobin (HBB2; SEQ ID NO:1), (b) the beta subunit of human hemoglobin (HBB; SEQ ID NO:2), (c) the 91 amino acid C-terminal fragment of HBB set forth in SEQ ID NO:4 (termed “HBB91”), (d) the 15 amino acid fragment of HBB set forth in SEQ ID NO:5 (termed “HBB11p” and “Metox”), (e) functional fragments of HBB2, HBB and HBB91, (f) functional variants of HBB2, HBB, HBB91, HBB11p and the functional fragments, and (g) functional derivatives of each of the proteins and peptides of (a) through (f).

**[0058]** As used herein, “functional fragments” are those having at least about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids of HBB2, HBB or HBB91. Each of the functional fragments retains the activity of the protein or peptide upon which a particular fragment is based.

**[0059]** As used herein, “functional variants” are those having at least about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence homology to the protein or peptide upon which they are based, or that have X or fewer amino acids changes, where X is 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1, in comparison to the protein or peptide upon which they are based. The changes are independently selected from additions, deletions and substitutions. The substitutions may be conservative or non-conservative amino acid substitutions. Each of

the functional variants retains the activity of the protein or peptide upon which a particular variant is based.

**[0060]** As used herein, “functional derivatives” include, but are not limited to, proteins and peptides comprising one or more L-amino acids, proteins and peptides comprising one or more D-amino acids, proteins and peptides comprising one or more synthetic amino acids, cyclized peptides, peptides with derivatized amino acids, chimeric peptides wherein an HBB peptide is fused to another peptide or polypeptide, HBB peptides fused to other chemical moieties, HBB peptides enclosed within liposomes or nanoparticles or hydrogels, and the like. Also included are (i) the D-enantiomer or inverso-peptide having the same sequence as the reference protein or peptide, but composed of D-amino acids and a mirror conformation; (ii) the retro-peptide, consisting of the same sequence of L amino acids but in reverse order; and (iii) the retro-inverso or D-retro-enantiomer peptide, consisting of D-amino acids in the reversed sequence. Each of the functional derivatives retains the activity of the protein or peptide upon which a particular derivative is based.

#### Pharmaceutical Formulations

**[0061]** The invention provides pharmaceutical formulations comprising one or more of the HBB peptides of the invention and a pharmaceutically acceptable carrier. Such formulations may be administered to a subject, such as a human. Suitable examples of carriers are well known to those skilled in the art and include water, water-for-injection, saline, buffered saline, dextrose, glycerol, ethanol, propylene glycol, polysorbate 80 (Tween-80™), poly(ethylene)glycol 300 and 400 (PEG 300 and 400), PEGylated castor oil (e.g. Cremophor EL), poloxamer 407 and 188, hydrophilic and hydrophobic carriers, and combinations thereof. Hydrophobic carriers include, for example, fat emulsions, lipids, PEGylated phospholipids, polymer matrices, biocompatible polymers, lipospheres, vesicles, particles, and liposomes. The terms specifically exclude cell culture medium. The formulations may further comprise stabilizing agents, buffers, antioxidants and preservatives, tonicity agents, bulking agents, emulsifiers, suspending or viscosity agents, inert diluents, fillers, and combinations thereof.

#### Micrometastases

**[0062]** Metastasis is the spread of a cancer from its original location to other sites in the body, where secondary tumors are formed. These secondary tumors initially comprise such a small number of cells that there are very difficult to detect in a subject. At the stage when the

secondary tumors are too small to be detected by conventional means, the tumors are termed “micrometastases”. As used herein, micrometastases are not limited to the cells of a particular tumor or cancer. However, in one aspect, the present invention encompasses micrometastases comprising neuroblastoma cells. Such micrometastases are termed “MicroNB”.

#### Methods of Screening

**[0063]** The presence of micrometastases in the organs and systems of a subject is nearly impossible to detect due to their scarcity and the absence of detection methods.

**[0064]** Described herein is the first report that the expression level of HBB is elevated in organs harboring micrometastases and in the serum of micrometastases-bearing subjects. Accordingly, HBB peptides can serve as biomarkers for the presence of micrometastases, as well as predicting tumor progression. For example, HBB peptide levels in the serum of a subject can be measured to determine the presence of micrometastases. HBB peptide levels can also be used to indicate the efficacy of particular treatments, thereby guiding the choice of treatment regimens and decisions. In a general aspect, the invention includes methods of screening a subject for micrometastases comprising (a) obtaining a biological sample from a subject, (b) determining the amount of an HBB peptide in the sample, and (c) comparing to amount determined in (b) with a reference amount.

**[0065]** The micrometastases to be screened can be comprised of cells originating from any type of cancer, including breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the micrometastases are neuroblastomal in origin.

**[0066]** The characteristics of a subject to be screened are not limited and can include one that has not previously been diagnosed or suspected of having micrometastases, one that currently has micrometastases, or one that previously had micrometastases but was shown to be free of micrometastases.

**[0067]** The biological sample is as defined herein; an exemplary biological sample is serum.

**[0068]** The identity of the HBB peptide to be screened is as defined herein, but exemplary forms include native hemoglobin beta subunit, such as native human hemoglobin beta subunit (i.e., HBB).

**[0069]** The amount of HBB peptide may be determined by conventional means for either determining whether a particular protein is present in a biological sample and/or determining the amount of a particular protein in a biological sample. Such means include western blot

analysis, dot- or slot-blot analysis, and enzyme-linked immunosorbent assays (ELISA). Additional means include RP-HPLC (reversed-phase high-performance liquid chromatography), LC-MS (liquid chromatography–mass spectrometry) and LC-MS/MS (liquid chromatography tandem mass spectrometry).

**[0070]** The reference amount of HBB peptide used in the present method is one determined from a subject or group of subject that has been previously characterized with respect to the presence and/or amount of micrometastases present in the subject or group of subject. A comparison using the reference amount permits one to determine whether micrometastases are present in the subject and the amount of micrometastases present in the subject. While not intending to be bound by theory, the higher the amount of HBB peptides determined to be present in the biological sample, the more likely it is that the subject has micrometastases.

**[0071]** In a particular example of this aspect of the invention, when the amount determined in (b) is more than the reference amount, the subject is diagnosed as having micrometastases. In another particular aspect, when the amount determined in (b) is the same as or less than the reference amount, the subject is diagnosed as being free of micrometastases.

#### Methods of Treatment and Inhibition

**[0072]** The invention is also directed to therapeutic uses for HBB peptides. As shown in the examples, HBB peptides can have cytostatic and cytotoxic effects on cancer cells. Thus, the HBB peptides, and pharmaceutical formulations comprising the peptides, can be used in methods of treating and inhibiting cancer in a subject.

**[0073]** In one aspect, the invention is directed to methods of treating a subject having cancer comprising administering an effective amount of an HBB peptide to the subject. In a non-limiting example, the cancer is neuroblastoma.

**[0074]** In a second aspect, the invention is directed to methods of inhibiting development of cancer in a subject at risk of developing cancer comprising administering an effective amount of an HBB peptide to a subject at risk of developing cancer. In a non-limiting example, the cancer is neuroblastoma.

**[0075]** In a third aspect, the invention is directed to methods of inhibiting metastasis of a cancer in a subject having cancer comprising administering an effective amount of an HBB peptide to a subject having cancer. In a non-limiting example, the cancer is neuroblastoma.

**[0076]** In first related aspect, the invention is directed to methods of inducing cytostasis in the cells of a cancer or tumor in a subject comprising administering an effective amount of an HBB peptide to the subject. In a non-limiting example, the cancer is neuroblastoma.

**[0077]** In second related aspect, the invention is directed to methods of inducing cytostasis in the cells of a cancer or tumor comprising contacting cells of a cancer or tumor with an effective amount of an HBB peptide. In a non-limiting example, the cancer is neuroblastoma.

**[0078]** In third related aspect, the invention is directed to methods of inducing cell cycle arrest in the cells of a cancer or tumor in a subject comprising administering an effective amount of an HBB peptide to the subject. In a non-limiting example, the cancer is neuroblastoma. In a non-limiting example, the cell cycle arrest is in the G0-G1 phase.

**[0079]** In fourth related aspect, the invention is directed to methods of inducing cell cycle arrest in the cells of a cancer or tumor comprising contacting cells of a cancer or tumor with an effective amount of an HBB peptide. In a non-limiting example, the cancer is neuroblastoma. In a non-limiting example, the cell cycle arrest is in the G0-G1 phase.

**[0080]** In each of these aspects of the invention related to methods of treatment and inhibition, the methods can be practiced using HBB peptides alone or practiced in conjunction with additional means for treating and inhibiting cancer in a subject. Such additional means will be well known to the skilled artisan and include, but are not limited to means such as anti-cancer chemotherapeutics and surgical removal of a tumor.

**[0081]** As used herein, the terms “treat”, “treating” and “treatment” have their ordinary and customary meanings, and include one or more of complete or partial clearance of a tumor or cancer from a subject, reducing the size of a tumor in a subject, killing cells of a tumor or cancer in a subject, and ameliorating a symptom of cancer or a tumor in a subject. Treatment means clearing, reducing, killing or ameliorating by about 1% to about 100% versus a subject to which an HBB peptide has not been administered. Preferably, the clearing, reducing, killing or ameliorating is about 100%, about 99%, about 98%, about 97%, about 96%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5% or about 1%. The results of the treatment may be permanent or may continue for a period of days (such as 1, 2, 3, 4, 5, 6 or 7 days), weeks (such as 1, 2, 3 or 4 weeks), months (such as 1, 2, 3, 4, 5, 6 or more months) or years (such as 1, 2, 3, 4, 5, 6 or more years).

**[0082]** As used herein, the terms “inhibit”, “inhibiting” and “inhibition” have their ordinary and customary meanings, and include one or more of, hindering, impeding, obstructing, deterring or restraining establishment of cancer or a tumor, development of cancer or a tumor, growth of cancer or a tumor and metastasis. Inhibition means hindering by about 1% to about 100% versus a subject to which an HBB peptide has not been administered. Preferably, the hindering is about 100%, about 99%, about 98%, about 97%, about 96%, about 95%, about

90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5% or about 1%. The methods of inhibition may be practiced in a subject prior to, concurrent with, or after the onset of clinical symptoms of cancer or a tumor. Thus, the subject may have cancer or a tumor, or merely be susceptible to developing cancer or a tumor. The results of the inhibition may be permanent or may continue for a period of days (such as 1, 2, 3, 4, 5, 6 or 7 days), weeks (such as 1, 2, 3 or 4 weeks), months (such as 1, 2, 3, 4, 5, 6 or more months) or years (such as 1, 2, 3, 4, 5, 6 or more years).

**[0083]** The HBB peptides and formulations comprising HBB peptides may be administered to a subject using different schedules, depending on the particular aim or goal of the method; the age and size of the subject; and the general health of the subject, to name only a few factors to be considered. In general, the HBB peptides and formulations may be administered once, or twice, three times, four times, five times, six times or more, over a course of treatment or inhibition. The timing between each dose in a dosing schedule may range between days, weeks, months, or years, an includes administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more weeks. The same quantity of HBB peptide may be administered in each dose of the dosing schedule, or the amounts in each dose may vary. The identity of the HBB peptide may also vary or remain the same in each dose in a dosing schedule.

**[0084]** In each of the methods of the present invention, an “effective amount” of an HBB peptide or pharmaceutical formulation comprising an HBB peptide is administered to a subject. The effective amount will vary between subjects. However, the effective amount is one that is sufficient to achieve the aim or goal of the method, whether inhibiting or treating. As an example, an effective amount of an HBB peptide used in the methods of the invention is typically between about 0.1  $\mu\text{g}$  to about 10,000  $\mu\text{g}$  of HBB peptide per kg of body weight of the subject to which the peptide is administered. An effective amount also includes between about 0.5  $\mu\text{g}$  to about 5000  $\mu\text{g}$ , between about 1  $\mu\text{g}$  to about 500  $\mu\text{g}$ , between about 10  $\mu\text{g}$  to about 200  $\mu\text{g}$ , between about 1  $\mu\text{g}$  to about 800  $\mu\text{g}$ , between about 10  $\mu\text{g}$  to about 1000  $\mu\text{g}$ , between about 50  $\mu\text{g}$  to about 5000  $\mu\text{g}$ , between about 50  $\mu\text{g}$  to about 500  $\mu\text{g}$ , between about 100  $\mu\text{g}$  to about 1000  $\mu\text{g}$ , between about 250  $\mu\text{g}$  to about 2500  $\mu\text{g}$ , between about 500  $\mu\text{g}$  to about 2000  $\mu\text{g}$ , between about 10  $\mu\text{g}$  to about 800  $\mu\text{g}$ , between about 10  $\mu\text{g}$  to about 1000  $\mu\text{g}$ , between about 1  $\mu\text{g}$  to about 300  $\mu\text{g}$ , and between about 10  $\mu\text{g}$  to about 300  $\mu\text{g}$  of HBB peptide per kg of body weight of the subject.

[0085] Appropriate doses and dosing schedules can readily be determined by techniques well known to those of ordinary skill in the art without undue experimentation. Such a determination will be based, in part, on the tolerability and efficacy of a particular dose.

[0086] Administration of the HBB peptide or formulation may be via any of the means commonly known in the art of peptide delivery. Such routes include intravenous, intraperitoneal, intramuscular, subcutaneous and intradermal routes of administration, as well as nasal application, by inhalation, ophthalmically, orally, rectally, vaginally, or by any other mode that results in the HBB peptide or formulation contacting mucosal tissues.

[0087] As used herein, the cancer and tumor are not limited and include, for example, breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma.

[0088] As used herein, the term “biological sample” includes tissues (e.g., tissues obtained during a biopsy, including the clean margins of the resected tissue), cells, biological fluids (e.g., blood, serum, plasma, saliva, sputum, sweat, urine) and isolates thereof, isolated from a subject, as well as tissues, cells and fluids present within a subject.

[0089] As used herein, the term “subject” is intended to mean an animal, such birds or mammals, including humans and animals of veterinary or agricultural importance, such as dogs, cats, horses, sheep, goats, and cattle.

[0090] A kit comprising the necessary components for practicing the methods disclosed herein is also within the purview of the present invention. The kit comprises one or more HBB peptides and instructions for use. In some aspects, the one or more HBB peptides are in a pharmaceutical formulation comprising the HBB peptides and a pharmaceutically acceptable carrier.

#### Uses of the HBB peptides

[0091] In addition to the compositions and methods described herein, the present invention is also directed to uses for the HBB peptides in various (i) methods of treatment or inhibition and (ii) methods of manufacture.

[0092] For example, the invention is directed to the use of an HBB peptide in one or more methods of (i) treating a subject having cancer, (ii) inhibiting development of cancer in a subject at risk of developing cancer, and (iii) inhibiting metastasis of cancer in a subject having cancer. In non-limiting examples, an effective amount of an HBB peptide is administered to a subject in each of these uses.

**[0093]** In each of these uses, the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma.

**[0094]** In a non-limiting example, the HBB peptide is used in a method of treating a subject having neuroblastoma, wherein an effective amount of an HBB peptide is administered to a subject having neuroblastoma.

**[0095]** In another non-limiting example, the HBB peptide is used in a method of inhibiting development of neuroblastoma in a subject at risk of developing neuroblastoma, wherein an effective amount of an HBB peptide is administered to a subject at risk of developing neuroblastoma.

**[0096]** In a further non-limiting example, the HBB peptide is used in a method of inhibiting metastasis of neuroblastoma in a subject having neuroblastoma, wherein an effective amount of an HBB peptide is administered to a subject having neuroblastoma.

**[0097]** When the use is one of inhibiting development of cancer in a subject at risk of developing cancer, the subject at risk of developing cancer may be a subject that was previously treated for cancer or neuroblastoma or the subject at risk of developing cancer may be a subject in which cancer or neuroblastoma was previously cured.

**[0098]** As suggested above, the invention is also directed to the use of an HBB peptide for the manufacture of a medicament for (i) treating cancer in a subject, inhibiting development of cancer in a subject at risk of developing cancer, and (iii) inhibiting metastasis of cancer in a subject having cancer. The cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system (e.g., neuroblastoma). In one example, the cancer is neuroblastoma.

**[0099]** In a non-limiting example, the HBB peptide is used for the manufacture of a medicament for treating neuroblastoma in a subject.

**[0100]** In another non-limiting example, the HBB peptide is used for the manufacture of a medicament for inhibiting development of neuroblastoma in a subject at risk of developing neuroblastoma.

**[0101]** In a further non-limiting example, the HBB peptide is used for the manufacture of a medicament for inhibiting metastasis of cancer in a subject having cancer.

### **Examples**

[0103] The eight examples provided further below each used the materials and methods detailed in the following paragraphs.

#### **Cell culture**

[0104] The human neuroblastoma lung micrometastatic (MicroNB) and macrometastatic (MacroNB) variants were generated using a mouse model for human neuroblastoma metastasis (Nevo et al., 2008) from the parental cell lines MHH-NB11 (Pietsch et al., 1988) and SH-SY5Y (Biedler et al., 1978) as detailed here (Edry Botzer et al., 2011), and were maintained in culture as previously described (Nevo et al., 2008). The MicroNB and MacroNB variants were previously designated DisNB and MetNB, respectively (Edry Botzer et al., 2011). Authentication of MicroNB and MacroNB cells was performed by short tandem repeat analysis of DNA using the Type-it Microsatellite PCR Kit (Qiagen, Valencia, CA), for the genes published by the American Type Culture Collection (ATCC) (Manassas, VA). The parental cell line MHH-NB11 was kindly provided by Dr. T. Pietsch (Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany).

[0105] All cultures were periodically examined for mycoplasma contamination.

#### **Animals**

[0106] Male athymic nude mice (BALB/c background) were purchased from Harlan Laboratories Limited (Jerusalem, Israel) or from the Shanghai Laboratory Animal Center (Chinese Academy of Sciences, Shanghai, People's Republic of China). The mice were housed and maintained for approximately 4 weeks in laminar flow cabinets under specific pathogen-free conditions at the animal quarters of Tel Aviv University (Tel Aviv, Israel) or of Fudan University (Shanghai, People's Republic of China), in accordance with current regulations and standards of institutional animal care committees. Mice of 7–10 weeks old were used for experiments in accordance with institutional ethical guidelines.

#### **Antibodies**

[0107] Goat polyclonal anti-mouse Hemoglobin  $\beta$  (sc-31116; Santa Cruz Biotechnology Inc., Santa Cruz, CA), was used at a dilution of 1:1000 for immunoblotting, at a dilution of 1:50 for immunofluorescence of frozen sections and at a concentration of 1 $\mu$ g/ml, 10 $\mu$ g/ml or 100 $\mu$ g/ml for neutralizing the inhibitory activity of lung-derived factors. Rabbit polyclonal anti-human ERK2 (C-14; Santa Cruz Biotechnology, Inc.), anti-human phosphorylated-

ERK1/2 (R&D Systems, Minneapolis, MN), anti-human phosphorylated-p38 MAPK (Thr180/Tyr182) (D3F9; Cell Signaling, Massachusetts, USA), anti-human p38 MAPK (M0800; Sigma-Aldrich, St. Louis, MO, USA), anti-human phosphorylated-TAK1 (Thr184/187) (90C7; Cell Signaling) and anti-human TAK1 (4504S; Cell Signaling) were used at a dilution of 1:1000 for immunoblotting. Mouse monoclonal anti-human Cyclin D1 (DCS-6; Thermo Scientific, Cheshire, UK) and mouse monoclonal anti-human  $\beta$ -Tubulin (T4026; Sigma-Aldrich) were used at a dilution of 1:500 and 1:2000, respectively, for immunoblotting. Horseradish peroxidase (HRP)-conjugated donkey anti-goat, goat anti-mouse and goat anti-rabbit antibodies were used according to the manufacturer instructions (Jackson ImmunoResearch Laboratories, West Grove, PA) for immunoblotting. Fluorescein isothiocyanate (FITC)-conjugated donkey anti-goat IgG (Jackson Immuno Research Laboratories) was diluted 1:200 for immunofluorescence of frozen tissues.

#### In vitro viability assays

**[0108]** Neuroblastoma cells were seeded ( $3 \times 10^4$  per well) in a 96-well flat-bottomed tissue culture plate. After an incubation of 24 hr, cells were washed and incubated with the relevant factors (detailed in the following sections) diluted in starvation medium (RPMI-1640 containing 5% bovine serum albumin (BSA); Biological Industries, Kibbutz Beit Haemek, Israel; Sigma-Aldrich). Cell viability under normal conditions (starvation medium containing BSA) or after incubation with the relevant factors was monitored after 72 hr using an XTT (XTT cell proliferation kit; Biological Industries) or MTS-based (CellTiter 96® AQueous One Solution Cell Proliferation Assay; Promega) viability assays according to manufacturer instructions. Cells were also counted using the trypan-blue exclusion assay to verify the results obtained by XTT and MTS-based viability assays.

#### Preparation of factors derived from mouse lungs

**[0109]** Lungs of one hundred 7-10 week old BALB/c athymic nude mice were used to prepare the lung-derived factors as previously described (Maman et al., 2013). In short, lungs were cut into pieces, suspended in serum-free medium (RPMI-1640) in a ratio of 1ml/1 lung (100mg tissue), manually minced, and centrifuged twice for 7 min at 1,200 rpm. The lung supernatants were then collected and filtered (0.45 $\mu$ m, Whatman GmbH, Germany). Lung supernatants were lyophilized and kept in -80°C until use. The factors collected in this manner were referred hereafter as lung-derived factors.

#### Dialysis of lung-derived factors

[0110] Lyophilized lung-derived factors were reconstituted in serum-free medium (RPMI-1640) to a concentration of 1mg/ml, filtered (0.45µm) and injected into a 3500Da cutoff dialysis cassette (3.5K MWCO Slide-A-Lyzer; Thermo Scientific). The dialysis cassette was stirred for 24 hr in a 1XDulbecco's Phosphate Buffered Saline (Sigma-Aldrich) that was changed twice. Dialyzed and non-dialyzed lung-derived factors were then supplemented with 5% BSA and incubated with neuroblastoma cells for 72 hr and cell viability was assessed as described below.

#### HPLC separation of lung-derived factors

[0111] Lyophilized lung-derived factors were reconstituted in Milli-Q purified water (EMD Millipore) to a concentration of 1mg/ml, filtered (0.45µm) and subjected to separation by Alliance reversed-phase high-performance liquid chromatograph (RP-HPLC) (Waters, Milford, MA) system using Waters XBridge C18 column (30X150mm, 5µm) running a gradient of 35% to 50% acetonitrile (Fisher Scientific, Pittsburgh, PA, USA) in water containing 0.1% trifluoroacetic acid (Halocarbon, Inc., River Edge, NJ, USA) at a flow rate of 15 ml/min. Separated fractions were collected, lyophilized and reconstituted in starvation media (RPMI 5% BSA) to a concentration of 1mg/ml. The reconstituted fractions were then filtered (0.45µm), incubated with neuroblastoma cells at for 72 hr and cell viability was assessed as described below.

#### HPLC purification of the inhibitory fraction of lung-derived factors

[0112] The HPLC-separated fraction found to inhibit the viability of neuroblastoma cells was lyophilized and reconstituted in Milli-Q purified water (EMD Millipore, MA, USA) to a concentration of 1mg/ml, filtered (0.45µm) and subjected to high-resolution purification by Alliance RP-HPLC system (Waters) using Waters XBridge C18 column (30X150mm, 5µm) running a gradient of 30% to 50% acetonitrile (Fisher Scientific) in water containing 0.1% trifluoroacetic acid (Halocarbon), at a flow rate of 40ml/min. The purified fraction was collected, lyophilized, and reconstituted in starvation media (RPMI 5% BSA) to a concentration of 1mg/ml. The reconstituted purified inhibitory fraction was then filtered (0.45µm), incubated with neuroblastoma cells for 72 hr and cell viability was assessed as described below.

#### Electrospray ionization mass spectrometry

[0113] Electrospray ionization mass spectrometry (ESI-MS) analyses were carried out on a Micromass ZQ-4000 single quadrupole mass spectrometer (Waters). Samples were suspended in 50% methanol-1% acetic acid buffer and infused by a syringe pump at 10 $\mu$ l/min. Deconvolution of data was performed using the Micromass MaxEnt software.

#### Tryptic digestion of the purified inhibitory factor

[0114] The direct digestion of the purified inhibitory factor was performed in Coomassie stained polyacrylamide gel. Protein spots were excised from the gel and in gel digested with trypsin according to published procedures (Rosenfeld et al., 1992). The gel pieces were dehydrated in acetonitrile (Fisher Scientific), rehydrated in 10mM dithiothreitol (DTT) in 0.1M ammonium bicarbonate and reduced at room temperature for 30 min. The DTT solution was removed and the sample alkylated 30 $\mu$ l 50mM iodoacetamide in 0.1M ammonium bicarbonate at room temperature for 30 min. The reagent was removed and the gel pieces dehydrated in acetonitrile. The acetonitrile was removed and the gel pieces rehydrated in 0.1M ammonium bicarbonate. The pieces were dehydrated in acetonitrile, the acetonitrile removed and the pieces completely dried by vacuum centrifugation. The gel pieces were rehydrated in 20ng/ $\mu$ l trypsin in 50 mM ammonium bicarbonate on ice for 10 min. Any excess enzyme solution was removed and 50mM ammonium bicarbonate added. The sample was digested overnight at 37 $^{\circ}$ c in 50% acetonitrile and 5% formic acid and evaporated to for MS analysis.

#### Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

[0115] The LC-MS system consisted of a Thermo Electron Orbitrap Velos ETD mass spectrometer system with a Protana nanospray ion source interfaced to a self-packed 8cmx75 $\mu$ m id Phenomenex Jupiter 10 $\mu$ m C18 reversed-phase capillary column. The digested inhibitory factor was injected and the peptides eluted from the column by an acetonitrile-0.1M acetic acid gradient at a flow rate of 0.5 $\mu$ l/min over 30 min. The nanospray ion source was operated at 2.5 kV. The digest was analyzed using the double play capability of the instrument acquiring full scan mass spectra to determine the peptide molecular mass followed by product ion spectra to determine amino acid sequence in sequential scans. The data were analyzed by database searching using the Sequest search algorithm against the Mouse International Protein Index (IPI).

#### Blocking the inhibitory effect of lung-derived factors

[0116] Lung-derived factors were supplemented with 1, 10 or 100µg/ml of either control goat IgG Isotype antibody (AB-108-C; R&D Systems) or of specific goat anti-mouse HBB2 antibody (M-19; Santa Cruz Biotechnology). The antibody-supplemented lung-derived factors were then incubated with neuroblastoma cells for 72 hr and cell viability was assessed as described below.

#### Orthotopic inoculation of tumor cells

[0117] An orthotopic inoculation to the adrenal gland of athymic nude mice was performed with either 50µl of PBSX1 supplemented with 5% BSA, or with  $1 \times 10^6$  MicroNB cells (generated as described previously (Edry Botzer et al., 2011)) suspended in 50µl of PBSX1 supplemented with 5% BSA. The intra-adrenal inoculation was performed as detailed here (Nevo et al., 2008). In short, anesthesia was induced by ketamine (100mg/kg body weight) and 2% xylazine (10mg/kg body weight) administered intraperitoneally. Tumor cells ( $1 \times 10^6/50\mu\text{l}$ ) or PBSX1 5%BSA (50µl) were injected orthotopically into the left adrenal gland of nude mice.

#### Monitoring tumor growth and metastasis

[0118] The development of local tumors in the adrenal gland was monitored and measured weekly with an external digital caliper. The tumor volume in  $\text{mm}^3$  was calculated by the ellipsoid volume calculation formula:  $\text{Volume} = 0.5 \times (\text{length} \times \text{width}^2)$  (Tomayko and Reynolds, 1989). At the end of the experiments, local adrenal tumors were weighed.

[0119] For examining the presence of micrometastatic cells in the lungs and bone marrow of mice, organs were harvested at the end of the experiment, and immediately snap frozen in dry ice. RNA was isolated from frozen tissues and used for the generation of first-strand cDNA using an M-MLV Reverse Transcriptase (See below, “RNA preparation and Reverse Transcription Polymerase Chain Reaction”). Quantification of human cells in mouse organs was determined by quantitative real-time PCR (qRT-PCR) assays.

#### RNA preparation and Reverse Transcription Polymerase Chain Reaction

[0120] Total cellular RNA was extracted using EZ-RNA Total RNA Isolation Kit (Biological Industries) according to the manufacturer instructions. RNA concentrations were determined by the absorbance at 260nm and quality control standards were  $A_{260}/A_{280} = 1.8 - 2.0$ . RNA samples were used for cDNA synthesis using the M-MLV Reverse Transcriptase (Applied

Biosystems Inc.) according to the manufacturer's instructions.

#### Quantitative Real-Time PCR

[0121] Quantification of cDNA was performed on Rotor-gene 6000<sup>TM</sup> (Corbett life science, Australia), utilizing Rotor gene 6000 series software. Reactions were run in triplicates. Transcripts were detected using SYBR Green I (Thermo Fisher Scientific, ABgene, Hamburg, Germany), according to the manufacturer instructions. The reaction primers designed based on gene sequences obtained from the GenBank Nucleotide Database of the NCBI website are described in Table 1. The mRNA concentration of the target genes was normalized to the mRNA concentration of the normalizing housekeeping genes, human beta-2-microglobulin (h $\beta$ 2M) or mouse beta-2-microglobulin (m $\beta$ 2M). The detection of micrometastatic human neuroblastoma cells in mouse tissues was performed as previously described (Edry Botzer et al., 2011).

Table 1

Gene Name	Specificity	Accession Number	Sequence	SEQ ID NO:
$\beta$ 2M	Human	NM_004048.2	S - 5'-ATGTAAGCAGCATCATGGAG-3'	7
			AS - 5'-AAGCAAGCAGAATTTGGAAT-3'	8
$\beta$ 2M	Mouse	NM_009735.3	S - 5'-CTGGTCTTTCTGGTGCTTGT-3'	9
			AS - 5'-GGCGTGAGTATACTTGAATTTGAG-3'	10
CXCL10	Mouse	NM_021274.2	S - 5'-CTATCCTGVVACGTGTGA-3'	11
			AS - 5'-CTTGATGGTCTTAGATTCCGG-3'	12
CX3CL1	Mouse	NM_009142.3	S - 5'-GGCCGCGTTCTTCCATTTGT-3'	13
			AS - 5'-GATTCGCATTTGTCATGC-3'	14
HBB2	Mouse	NM_016956.3	S - 5'-GTGACAAGCTGCATGTGGAT-3'	15
			AS - 5'-AGGTGGTGGCCAGCACAAT-3'	16

S-sense primer, AS- antisense primer.

#### Fixation and sectioning of frozen tissues

[0122] Lungs of athymic nude mice that were orthotopically inoculated to the adrenal gland with either PBSX1 (normal mice) or MicroNB cells (micrometastasis-bearing mice) were washed in cold PBSX1 and put in 4% paraformaldehyde (Bio-Lab Ltd., Jerusalem, Israel) for 2 hr. Lungs were then put in 0.5M sucrose for 1 hr and in 1M sucrose in 4°C over night. Lungs were embedded in OCT (Tissue-Tek; Bar-Naor Ltd, Israel) for 1 hr in 4°C and then frozen in OCT on dry ice. Blocks were stored in -80°C until sectioning. Sections of 10 $\mu$ M were cut by Leica CM1860 Clinical histopathology cryostat (Leica Biosystems, Nussloch

GmbH, Germany), mounted on Superfrost slides (Menzel-Glazer, Braunschweig, Germany) and air dried for 20 min. Slides were stored in -80°C until immunofluorescence staining.

#### Immunofluorescence of frozen tissue sections

[0123] Paraformaldehyde-fixed, OCT-embedded 10µm thick sections of mouse lungs were washed 3 times in PBSX1 and blocked with serum-free protein block (X0909; DakoCytomation) for 10 min. Sections were incubated with HBB2 diluted 1:50 in PBSX1 (See “Antibodies”) for 1 hour at room temperature followed by 3 times wash with PBSX1. Appropriate fluorescently conjugated secondary antibodies were then incubated with the slides for 30 minutes at room temperature. Coverslips were mounted on fluorescently labeled tissue using Vectamount mounting medium with DAPI (Vector Laboratories Burlingame, CA, USA). Fluorescent images were collected with a 63X1.4 oil objective in a Leica DM4000B fluorescence microscope using Leica LAS AF software (Leica Biosystems). Tissues were stained with secondary antibodies as controls.

#### Protein extraction from mouse organs

[0124] Lungs, bone marrow and liver of normal mice or of micrometastasis-bearing mice were washed twice in ice-cold PBSX1 and 100mg tissue was minced manually in 500µl ice-cold organ lysis buffer (0.05% Tween-20, 0.01% Sodium azide, 2µg/ml aprotinin, 2µg/ml leupeptin and 1mM PMSF in DDW). Lysates were incubated for 20 min on ice. Supernatants were collected after centrifugation at 16,000g for 20 min at 4°C. BCA Protein Assay (Pierce, Thermo Scientific) was used to determine protein concentration. Clarified extracts were aliquoted and stored at -80°C until used in western blot and Enzyme-Linked Immunosorbent Assays (ELISA).

#### Protein extraction from neuroblastoma cells

[0125] Neuroblastoma cells were washed twice with ice-cold PBSX1 and lysed with RIPA lysis buffer as previously described (Edry Botzer et al., 2011). Lysates were incubated for 20 min on ice and cleared by centrifuging at 16,000g for 20 min at 4°C. BCA Protein Assay (Pierce, Thermo Scientific) was used to determine protein concentration. Clarified extracts were aliquoted and stored at -80°C until used in western blot analyses.

#### Western blotting

**[0126]** Lysates of neuroblastoma cells and of mouse organs were resolved on SDS-PAGE after the addition of Laemmli sample buffer, and transferred onto nitrocellulose membrane. The total amount of protein in the lanes was assessed by Ponceau staining prior to blocking of the membrane. The membrane was blocked at room temperature with 3% BSA (Sigma-Aldrich) diluted in TBS-Tween (TBST) for 1 hr. For detection of the target proteins, membranes were incubated with relevant primary antibodies (see “Antibodies”), then washed 3 times x5 min with TBSTX1 and incubated with suitable HRP-conjugated secondary antibodies (see “Antibodies”). Membranes were washed again 5 times x3 min with TBSTX1. The bands were visualized by chemiluminescence-ECL reactions and autoradiography by exposure to Fuji film. The amount of the relevant protein in the lanes was estimated by densitometry using Scion Image software (Scion, Frederick, MD, USA).

#### Collection of mouse serum

**[0127]** Blood was collected from normal and micrometastasis-bearing mice from the retro-orbital plexus. One eyeball was pulled out and blood was collected into 1.5ml tube. Tubes were stored at room temperature for 1 hr. Tubes were then centrifuged for 15 min in 1500g at 4°C and serum supernatants were collected and stored in -80°C until used in western blot and ELISA assays.

#### Enzyme-Linked Immunosorbent assay

**[0128]** To determine the expression of mouse HBB2 in the serum of normal mice and of micrometastasis-bearing mice, HBB2 levels in mouse serum (see “Collection of mouse serum”) were determined by Enzyme-Linked Immunosorbent Assays (ELISA), using standard curves of mouse recombinant HBB2 (ChinaPeptides Co, Ltd, Shanghai, People's Republic of China) at the linear range of absorbance. The following antibodies were used: Coating: 5µg/ml goat anti-mouse Hemoglobin β antibody (M-19; Santa Cruz), detection: 0.25µg/ml biotinylated rabbit anti-mouse Hemoglobin β antibody (Cusabio, Wuhan, People's Republic of China). Following the addition of Avidin-HRP (PeproTech, Inc., Rocky Hill, NJ), the substrate ABTS (PeproTech, Inc.) was added, and color development was monitored with a Bio-Tek FL500 ELISA plate reader (Bio-Tek Instruments, Winooski, VT, USA) at 405nm with wavelength correction set at 650nm, according to the manufacturer instructions. The results obtained in ELISA assays were verified in western blot analyses.

#### HPLC separation of native human hemoglobin

**[0129]** Native human hemoglobin was dissolved in Milli-Q purified water (EMD Millipore) to a concentration of 1mg/ml and filtered (0.45  $\mu$ m). Human hemoglobin was then chromatographed by Alliance RP-HPLC system (Waters) using Waters XBridge C18 column (50X250mm, 10 $\mu$ m) running a gradient of 35% to 50% acetonitrile (Fisher Scientific) in water containing 0.1% trifluoroacetic acid (Halocarbon) at a flow rate of 40ml/min. The alpha and beta subunits of hemoglobin (HBA and HBB, respectively) separated in the chromatography were collected and purified by reversed phase HPLC and their molecular masses were verified by ESI-MS (see “Electrospray ionization mass spectrometry”). The purified HBA and HBB subunits were lyophilized and kept in -80°C until use.

#### Cell cycle analysis

**[0130]** Neuroblastoma cells ( $5 \times 10^5$ ) were plated and after 24 hr, cells were incubated for 48 hr with HBB diluted in starvation medium (RPMI 5% BSA) to a concentration of 10 $\mu$ g/ml. Neuroblastoma cells incubated with starvation medium containing BSA alone served as control. Cells were pelleted, washed and resuspended in 0.5ml PBSX1, containing 0.05ml propidium iodide (PI) (P-4170, Sigma) (50 $\mu$ g/ml), and 0.05 ml Triton X-100 (Sigma-Aldrich). Flow cytometry analysis was performed using Becton Dickinson FACSort and CellQuest software (Becton Dickinson, Mountain View, CA).

#### Cyclin D1 expression

**[0131]** Neuroblastoma cells ( $5 \times 10^6$ ) were plated and after 24 hr cells were incubated for 48 hr with human HBB diluted in starvation medium (RPMI 5% BSA) to a concentration of 10 $\mu$ g/ml. Neuroblastoma cells incubated with starvation medium containing BSA alone served as control. At the end of the incubation period, cells were lysed (see “Protein extraction from neuroblastoma cells”), resolved on SDS-PAGE, and transferred onto nitrocellulose membrane (see “Western blotting”). Cyclin D1 expression was calculated in reference to  $\beta$ -tubulin expression in the lane as measured by densitometry using Scion Image software (Scion).

#### ERK1/2, p38 and TAK1 Phosphorylation

**[0132]** Neuroblastoma cells ( $5 \times 10^6$ ) were plated and after 24 hr the growth medium was replaced with starvation medium (RPMI 0.5% FCS) for 24 hr. Cells were then washed and incubated for 30 min with human HBB, diluted in starvation medium (RPMI without BSA) to a concentration of 10 $\mu$ g/ml. Neuroblastoma cells incubated with starvation medium alone

served as control. At the end of the incubation period, cells were lysed (see “Protein extraction from neuroblastoma cells”), resolved on SDS-PAGE, and transferred onto nitrocellulose membrane (see “Western blotting”). ERK1/2 phosphorylation was calculated in reference to total ERK2 protein, p38 and TAK1 phosphorylation was calculated in reference to total p38 and TAK1, respectively, as measured by densitometry using Scion Image software (Scion).

#### Inhibition of p38 MAP kinase

**[0133]** Neuroblastoma cells were seeded ( $3 \times 10^4$  per well) in a 96-well flat-bottomed tissue culture plate. After an incubation of 24 hr, cells were washed and incubated with human HBB diluted in starvation medium (RPMI 5% BSA) to a concentration of 10  $\mu$ g/ml. The p38 MAP kinase inhibitors SB203580 (559389; Calbiochem, EMD Millipore) and SB202190 (152121-30-7; Calbiochem, EMD Millipore) were added in a concentration of 0.1, 1 and 10  $\mu$ M to the neuroblastoma cells incubated with HBB. Cells incubated with HBB only or p38 MAP kinase inhibitors only served as control. After 72 hr of incubation cell viability was assessed as described below.

#### Cleavage of human HBB into two fragments

**[0134]** Human HBB was incubated at a concentration of 2mg/ml with 50mg/ml CNBr (Sigma-Aldrich) in 5% trifluoroacetic acid (Halocarbon). After an overnight cleavage at room temperature, the resulting fragments of human HBB were purified by Alliance RP-HPLC system (Waters) using Waters XBridge C18 column (30X150mm, 5 $\mu$ m) running a gradient of 35% to 50% acetonitrile (Fisher Scientific) in water containing 0.1% trifluoroacetic acid (Halocarbon), at a flow rate of 15ml/min. Two products resulted, N-terminal and C-terminal fragments of human HBB, and their molecular masses were verified by ESI-MS (see “Electrospray ionization mass spectrometry”). The N- and C-terminal fragments of human HBB were incubated with neuroblastoma cells. After 72 hr of incubation cell viability was assessed as described below.

#### Solid-phase synthesis of human HBB segments

**[0135]** Fmoc solid-phase synthesis was used to synthesize human HBB in 14 peptide segments of 15 amino acid residues each. Each segment was composed of 5 amino acid residues overlapping those of the preceding segment and 5 amino acid residues overlapping those of the following segment. Peptide sequences appear in Table 2. Peptide segments of

human HBB were purified to homogeneity by RP-HPLC, and their molecular masses were ascertained by ESI-MS by ChinaPeptides (ChinaPeptides.Co, Ltd). HBB peptide segments were lyophilized and reconstituted in starvation media (RPMI 5% BSA) to a concentration of 1, 10 or 100 µg/ml. The reconstituted peptides were then filtered (0.45µm), incubated with neuroblastoma cells at for 72 hr and cell viability was assessed as described below.

Table 2 - Artificial Sequence

Human HBB Peptide Segment	Peptide Sequence	SEQ ID NO:
1	VHLTPEEKSAVTALW	17
2	VTALWGKVVNDEVGG	18
3	DEVGGEALGRLLVVY	19
4	LLVVYPWTQRFFESF	20
5	FFESFGDLSTPDAVM	21
6	PDAVMGNPKVKAHGK	22
7	KAHGKKVLGAFSDGL	23
8	FSDGLAHLDNLKGTF	24
9	LKGTFA TLSELHCDK	25
10	LHCDKLHVDPENFRL	26
11	ENFRLLGNVLCVLA	5
12	VCVLAHHFGKEFTPP	27
13	EFTPPVQAAYQKVVA	28
14	QKVVAGVANALAHKYH	29

#### Solid-phase synthesis of Metox and scrambled-Metox peptides

**[0136]** The short inhibitory C-terminal human HBB peptide (ENFRLLGNVLCVLA; SEQ ID NO:5) designated “HBB11p” or “Metox”, and a control peptide of a scrambled amino acid sequence (ANVLNECVFVGRLLL; SEQ ID NO:6) designated scrambled-Metox, were chemically synthesized. The synthesis was performed on appropriate PAM resins (Applied Biosystems) on an 433A peptide synthesizer (Applied Biosystems) using an optimized HBTU (Oakwood Chemical, West Columbia, SC, USA) activation/DIEA (Sigma-Aldrich) in-situ neutralization protocol developed by Kent and coworkers for Boc solid-phase peptide synthesis (Schnolzer et al., 1992). After chain assembly, the peptides were cleaved by anhydrous hydrogen fluoride (Airgas, PA, USA) in the presence of 5% p-cresol (Sigma-Aldrich) at 0°C for 1hr, followed by precipitation with cold ether. The Metox and scrambled-Metox peptides were purified to homogeneity by reversed-phase HPLC, and their molecular masses were ascertained by ESI-MS (see “Electrospray ionization mass spectrometry”).

#### Conjugation of Metox peptide to FITC

[0137] After chain assembly during Metox synthesis (see “Solid-phase synthesis of Metox and scrambled-Metox peptides”), Metox resin was conjugated to FITC (Life Technologies). The conjugation reaction proceeded overnight in DMF as solvent, in the molar Metox/FITC/DIEA ratio of 1:1.2 4. After hydrogen fluoride (Airgas, PA, USA) cleavage, crude Metox-FITC was dissolved in 50% Acetonitrile

#### Confocal microscopy for Metox cell entry

[0138] Neuroblastoma cells seeded on glass coverslips ( $8 \times 10^4$  per coverslip) overnight were treated with FITC-conjugated Metox at a concentration of  $10 \mu\text{g/ml}$ . The cells were washed with PBS after 30, 60 and 120 min of incubation with FITC-Metox and then fixed using 4% formaldehyde for 30 min. Coverslips were mounted on glass slides using Vectamount mounting medium with DAPI (Vector Laboratories Burlingame, CA, USA). Cells were analyzed by Leica TCS SP5 confocal microscope.

#### Treating mice with Metox

[0139] Mice were orthotopically inoculated with MicroNB cells to the adrenal gland to generate local adrenal tumors and lung and bone marrow micrometastasis (see “Orthotopic inoculation of tumor cells”). Fourteen days post tumor cell inoculation mice were treated either intravenously or intranasally with  $1 \text{mg/kg}$  ( $0.02 \text{mg/mouse}$ ) of the short inhibitory human HBB peptide, Metox, once a week for 8 weeks.

[0140] For intranasal administration of Metox, the lyophilized peptide was dissolved prior to each administration in Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich) to a concentration of  $0.013 \text{mg}/\mu\text{l}$ , and then diluted in sterile PBSX1 to a concentration of  $0.4 \mu\text{g}/\mu\text{l}$ . The dissolved peptide was filtered ( $0.2 \mu\text{m}$ ) and mice were forced to inhale  $50 \mu\text{l}$  of Metox ( $0.02 \text{mg/mouse}$ ). Control group was forced to inhale  $50 \mu\text{l}$  of a control scrambled peptide, scrambled-Metox (see “Solid-phase synthesis of Metox and scrambled-Metox peptides”).

#### Statistical analysis

[0141] Paired or unpaired Student t test was used to compare in-vitro and in-vivo results.

*Example 1. Lung-derived soluble extracts significantly inhibited the viability of MicroNB cells.*

[0142] Mouse lungs (ConLung) were harvested, minced and filtered, and soluble factors were collected as described above and as shown in **Fig. 1A**. Dialyzed and non-dialyzed lung-derived factors were prepared and incubated with MicroNB and MacroNB cells that were seeded ( $3 \times 10^4$  per well) a day earlier in a 96 well flat-bottomed tissue culture plate. After an incubation of 72 hr cell viability was assessed using an MTS-based viability assay. The MTS-based viability assays indicated that dialyzed (3500 MW Da cutoff) lung-derived factors inhibited cell viability to the same extent as non-dialyzed lung-derived factors. The results are shown in **Fig. 1B**. Data are means of three independent experiments  $\pm$ SD. Significance was evaluated using Student's t-test for the percentage of viable cells after incubation of MicroNB and MacroNB cells with dialyzed and non-dialyzed lung-derived factors compared to incubation with control media (No lung). Macro metastatic neuroblastoma cells (MacroNB) were found to be less sensitive to the lung-derived restraining factors and may have acquired resistance to these factors, thereby escaping their surveillance.

[0143] Given that the inhibitory activity of lung-derived factors was not impaired after a dialysis using a 3500Da membrane cassette, the molecular weight of the inhibitory factor was predicted to be higher than 3500Da. **Fig. 1C** shows that reversed-phase HPLC separation of dialyzed lung-derived factors resulted in four distinctive peaks. **Fig. 1D** shows the results from an MTS-based viability assay and trypan blue exclusion assays which revealed that peak no. 4 inhibited cell viability when incubated with micrometastatic (MicroNB) and macrometastatic (MacroNB) neuroblastoma cells for 72 hr. Data are means of three independent experiments  $\pm$ SD. Significance was evaluated using Student's t-test for the percentage of viable cells after incubation of MicroNB and MacroNB cells with HPLC-separated peaks of lung-derived factors compared to incubation with control media (No lung). **Fig. 1E** shows that HPLC purification of peak no. 4 resulted in one peak.

*Example 2. Isolation and identification of inhibitory lung factor.*

[0144] Identification of the isolated inhibitory lung factor. Electrospray ionization mass spectrometry (ESI-MS) analysis of the HPLC-separated peak no. 4 indicated that the peak harbored a single protein of a MW of 15824.5 Da (**Fig. 2A**). Sequence analysis by liquid chromatography-tandem mass spectrometry LC-MS/MS coupled with tryptic digestion of the inhibitory peak no. 4 revealed a 147 amino acid sequence (**Fig. 2B**). Database search in the

International Protein Index (IPI) revealed a 100% identity to the mouse beta subunit of hemoglobin (HBB2). HBB2 has the following amino acid sequence:

MVHLTDAEKSAVSVCLWAKVNPDEVGGALGRLLVVYPWTQRYFDSFGDLSSASAI  
MGNPKVKAHGKKVITAFNEGLKNLDNLKGTFFASLSELHCDKLHVDPENFRLLGNAI  
VIVLGHHLGKDFTPAAQAAFQKVVAGVATALAHKYH (SEQ ID NO: 1; GenBank  
accession number: Q549D9)

[0145] HBB2 was verified as the inhibitory lung factor when the addition of a specific anti-mouse HBB2 antibody blocked the inhibitory activity of lung-derived factors incubated with MicroNB and MacroNB cells, as indicated in an MTS-based viability assay (**Fig. 2C**). Lung-derived factors were supplemented with 0.1, 1 or 10 $\mu$ g of either control goat anti mouse IgG Isotype antibody (Jackson Immuno Research Laboratories) or of specific goat anti mouse HBB2 antibody (M-19; Santa Cruz). The antibody supplemented lung-derived factors were then incubated with MicroNB and MacroNB cells that were seeded ( $3 \times 10^4$  per well) a day earlier in a 96 well flat-bottomed tissue culture plate. After an incubation of 72 hr, cell viability was assessed using an MTS-based viability assay (CellTiter 96 $\text{\textcircled{R}}$  AQueous One Solution Cell Proliferation Assay, Promega) according to the manufacturer instructions. Data are means of three Independent experiments  $\pm$ SD. Significance was evaluated using Student's t-test for the percentage of viable cells after incubation of MicroNB and MacroNB cells with lung-derived factors (Conlung) or with lung-derived factors supplemented with a specific anti-mouse HBB2 antibody (Conlung +ab) compared to incubation with control media (No lung).

*Example 3. Human hemoglobin beta inhibits viability of neuroblastoma cells.*

[0146] The beta subunit of human hemoglobin (HBB) is known to be expressed ubiquitously in normal human lungs (Ishikawa et al., 2010). Whether HBB also has the capacity to inhibit the viability of human neuroblastoma metastases and micrometastases was investigated.

[0147] Native human hemoglobin (Sigma) was dissolved in Milli-Q purified water (Millipore Corporation) and filtered (0.45  $\mu$ m; Whatman GmbH, Germany). Human hemoglobin was then chromatographed by C18 reversed phase HPLC running a gradient of 30% to 50% acetonitrile in water containing 0.1% TFA at a flow rate of 1 ml/min. The alpha and beta subunits of hemoglobin separated in the chromatography were collected and purified by reversed phase HPLC and their molecular masses were verified by electrospray ionization mass spectrometry (ESI-MS). The beta subunit (HBB) had a MW of 15867 Da (**Fig. 3A**).

[0148] The 147 amino acid sequence of wild-type human HBB is as follows:

MVHLTPEEKSAVTALWGKVVNDEVGGEALGRLLVVYPWTQRFFESFGDLSTPDAV  
MGNPKVKAHGKKVLGAFSDGLAHLNLLKGTFFATLSELHCDKLHVDPENFRLLGNV  
LVCVLAHHFGKEFTPPVQAAAYQKVVAGVANALAHKYH (SEQ ID NO: 2; GenBank  
accession number: P68871).

[0149] Structure prediction of human HBB by 1-TASSER tool revealed a helical structure C (**Fig. 3B**). Circular dichroism analysis of human hemoglobin (HB), hemoglobin subunit alpha (HBA) and subunit beta (HBB) indicated a helical structure for all three proteins (**Fig. 3C**). An MTS-based viability assay indicated that incubation with 10µg human HBB decreased the viability of MicroNB cells by 52% and of MacroNB cells by 29% (**Fig. 3D**). HBA did not influence cell viability (**Fig. 3D**). Neuroblastoma cells were seeded ( $3 \times 10^4$  per well) in a 96 well flat-bottomed tissue culture plate. After 24 hr of incubation cells were washed and incubated with human HBB dissolved in starvation medium (RPMI 5% BSA) to the indicated concentrations. Cell viability under normal conditions (starvation medium) or after incubation with human HBB was monitored after an incubation of 72 hr using an MTS-based viability assay (CellTiter 96® Aqueous One Solution Cell Proliferation Assay, Promega) according to the manufacturer instructions. Data are means of three independent experiments  $\pm$ SD. Significance was evaluated using Student's t-test for each variant incubated with human HBB compared to incubation with control media (con).

[0150] Trypan blue exclusion assays (results not shown) demonstrated that 16% and 8% of MicroNB and MacroNB cells, respectively, were non-viable following the incubation with HBB. These results were strikingly similar to the cytostatic activities mediated by mouse lung-derived factors (Maman, S. et al. (2013). *Int J Cancer* 133, 2296-2306) or by mouse lung-derived HBB2. The HBB-mediated inhibitory activity was dose dependent (results not shown).

[0151] The influence of human HBB on cell viability was assessed on numerous additional cancerous cell lines as seen in Table 3. An inhibition in cell viability was observed in two cell lines when incubated with all HBB amounts examined (1, 10 and 100µg) – the lung carcinoma cell line A549 and the melanoma cell line RALL. When incubated with the highest amount of HBB (100µg), the viability of the following cell lines was inhibited: the breast cancer cell lines T47D and MCF-7, the prostate cancer cell line 22RVi, the cervical cancer cell line Hela, and the melanoma cell lines RALL and RKTJ.

**Table 3. The influence of HBB on the viability of numerous cancerous cell lines.**

Cell line	Tumor type	% difference in cell viability (1µg HBB)	% difference in cell viability (10µg HBB)	% difference in cell viability (100µg HBB)
MDA-231	Breast	No change	+5%	No change
MDA-MB-468		No change	No change	No change
T47D		No change	-8%	-30%
MCF-7		No change	No change	-26%
SKBR3		No change	No change	No change
SW480	Colon	No change	No change	No change
A549	Lung	-17%	-18%	-25%
22RVi	Prostate	No change	-14%	-45%
Hela	Cervix	No change	No change	-30%
RKTJ	Melanoma	No change	No change	-65%
RALL		-11%	-25%	-55%
*MHH-NB11 (MicroNB)	Neuroblastoma	-23%	-42%	-62%

\*The influence of HBB on the viability of MicroNB cells served as positive control in the viability experiments.

**[0152]** The influence of HBB on the viability of the normal lung-residing cell lines HPEC (Human pulmonary endothelial cells) and HLMEC (Human lung microvascular endothelial cells) and on the normal kidney cell line 293T and 293A was examined as well. HBB did not influence the viability of these normal cells (data not shown).

**[0153]** The whole human hemoglobin protein inhibited cell viability as well but not to the same extent as HBB (**Fig. 3E**). Data are means of three independent experiments  $\pm$ SD. Significance was evaluated using Student's t-test for the percentage of viable cells after incubation with human HBB compared to incubation with control media (not shown).

*Example 4. Inhibition in neuroblastoma cell viability due to cell cycle arrest.*

**[0154]** In order to elucidate the mechanism underlying the inhibition in cell viability caused by human HBB, MicroNB and MacroNB cells were incubated with HBB (1 µg) for 48 hr. Whole cell lysates of MicroNB and MacroNB cells were subjected to western blot analysis and immunostaining. The phosphorylation of the extracellular signal-regulated kinase (ERK), playing a central role in cell proliferation, was found to be decreased in both MicroNB and MacroNB cells (**Fig. 4A**) though more evidently in MicroNB cells.

[0155] The cells were also subjected to measurement of cellular DNA content and cell cycle analysis using flow cytometry. Incubation with human HBB elevated the amount of MicroNB and MacroNB cells in the sub G0 phase, by 18% and 11%, respectively (data not shown). A notable elevation in the amount of cells in G0-G1 phase was observed in MicroNB and MacroNB cells incubated with human HBB (59% and 23% elevation, respectively) (**Fig. 4B**).

[0156] Whole cell lysates of MicroNB and MacroNB cells incubated with human HBB were subjected to western blot analysis and immunostaining. A significant decline in Cyclin-D1 expression was observed in MicroNB and MacroNB cells incubated with human HBB (**Fig. 4C**), supporting the evidence that HBB induces cell cycle arrest in these cells. The decrease in Cyclin-D1 expression was greater in MicroNB cells incubated with human HBB than in MacroNB cells incubated with the factor. Cyclin D1 expression was calculated in reference to beta-tubulin. Data are means of three independent experiments  $\pm$ SD. Significance was evaluated using Student's t-test for each analysis after incubation with HBB compared to incubation with control media.

[0157] Taken together, these results indicate that the inhibition in neuroblastoma cell viability caused by human HBB is mostly due to cell cycle arrest in G0-G1 phase. This cell cycle arrest may lead to dormancy of neuroblastoma cells, especially of MicroNB cells, that do not express a full metastatic phenotype.

*Example 5. Inhibitory activity of HBB lies in a short C-terminal fragment of the protein.*

[0158] In order to pin-point the active fragment of the human HBB protein, the protein was cleaved to two fragments using cyanogen bromide (CNBr). The cleavage resulted in N- and C-terminal fragments of HBB (**Fig. 5A**) (SEQ ID NOs:3 and 4). The influence of these two purified fragments on neuroblastoma cell viability was examined using MTS-based proliferation assay and trypan blue exclusion assay. The results indicated that the C-terminal fragment is responsible for the inhibitory activity (**Fig. 5B**). The N-terminal fragment also exhibited an inhibitory effect however to a lesser extent (**Fig. 5B**). Data are means of three independent experiments  $\pm$ SD. Significance was evaluated using Student's t-test for each variant incubated with N- or C- terminal fragments of human HBB compared to incubation with control media (not shown).

[0159] In order to narrow down the fragment responsible for the inhibitory activity of the HBB protein in a more precise manner, portions of HBB were synthesized in 14 segments, each segment comprising 15 amino acids of the protein, overlapping in 5 amino acids with the following and preceding segment. The 14 HBB peptides were incubated with MicroNB

cells and examined for their influence on cell viability. Peptide number 11 (amino acid sequence ENFRLLGNVLVCVLA; SEQ ID NO:5) significantly inhibited the viability of the cells (**Fig. 5C**). The inhibition in cell viability caused by peptide 11 (designated HBB11p) was even greater than that caused by HBB (**Fig. 5C**). Data are means of three independent experiments  $\pm$ SD. Significance was evaluated using Student's t-test for the percentage of viable cells after incubation with each human HBB peptide compared to the percentage of viable cells after incubation with control media. Thus, a short C-terminal region of HBB is responsible for *in vitro* and *in vivo* inhibitory activity.

*Example 6. HBB2 expression is elevated in mice harboring micrometastasis.*

[0160] The aim of the next set of experiments was to evaluate the expression of HBB2 in lungs of normal mice and in mice bearing human neuroblastoma xenografts with clinically undetectable lung micrometastasis.

[0161] Sixteen mice were orthotopically inoculated to the adrenal gland with either neuroblastoma micrometastases or PBS (control group). After 8 weeks, lungs, liver and bone marrow were harvested from the mice and blood was collected (**Fig. 6A**). Mouse organs were examined for the presence of human neuroblastoma cells using real time PCR (Edry Botzer, L. et al. (2011). *Am J Path* 179, 524-536) and for HBB2 expression using western blot analysis (**Fig. 6B, 6C**) and immunostaining of frozen sections (**Fig. 6D**). HBB2 expression was significantly higher in the serum and in the organs of mice harboring micrometastasis compared to its level in the serum and organs of normal mice (**Fig. 6B, 6C**), implying an inducible expression of HBB2. HBB2 expression in mouse lungs was verified in frozen sections of normal (ConLung) and micrometastasis-bearing lungs (MicLung) that were fluorescently stained with anti-mouse HBB2 antibody and with DAPI. The higher expression of HBB2 in lungs harboring micrometastases was verified by western blot analysis of lung tissue lysates (**Fig. 6D**). Thus, HBB serves as a biomarker for the presence of clinically undetectable neuroblastoma micrometastasis and the results indicate that human neuroblastoma micrometastases induces/up-regulates the expression of HBB2 in these tissues.

*Example 7. Treatment with HBB11p inhibits local tumor growth and metastasis.*

[0162] Twenty four mice were orthotopically inoculated to the adrenal gland with MicroNB cells. Two weeks post inoculation, mice were either intravenously (IV) injected with HBB11p or PBS, or forced to inhale a droplet of soluble HBB11p, once a week for 8 weeks (**Fig. 7A**). Mice were monitored weekly for tumor volume. At the end of the experiment, local tumors were weighed and organs were harvested and examined for human neuroblastoma cells and for HBB2 expression using real time PCR (**Fig. 7A**).

[0163] Local tumors of mice that were intravenously inoculated with HBB11p or forced to inhale a droplet of HBB11p were significantly smaller than local tumors of mice that were intravenously inoculated with PBS (**Fig. 7B, 7C**). Lung metastasis was significantly inhibited in mice treated with HBB11p compared to mice treated with PBS (**Fig. 7D**). Liver, spleen and bone marrow metastasis were significantly inhibited as well in these mice (data not shown). Using real time PCR, HBB2 expression in each organ was found to correlate with the amount of micrometastasis in each organ (**Fig. 7E**), implying that elevating HBB2 expression in the presence of micrometastasis is the host attempt to inhibit tumor progression.

*Example 8. Treatment with HBB11p inhibits local tumor growth and metastasis.*

[0164] In an experiment similar to that described in Example 7, athymic nude mice were orthotopically inoculated with MicroNB cells to the adrenal gland. Fourteen days following inoculation, the mice were treated intranasally once a week for eight weeks with 1mg/kg HBB11p (“Metox”) or with the same amounts of a control peptide having the identical amino acid composition as Metox but in a scrambled sequence (“Scrambled-Metox”) (**Fig. 8A**). Mice were monitored for tumor volume on a weekly basis.

[0165] Twenty days after tumor cell inoculation a difference was apparent in local tumor volume between mice treated with Metox and mice treated with scrambled-Metox (**Fig. 8B**). This difference became more significant with time (**Fig. 8B**). Mice were euthanized 70 days post tumor cell inoculation and the resected local adrenal tumors were weighed. The weight of local tumors resected from scrambled-Metox treated mice was significantly higher than that of local adrenal tumors resected from mice treated intranasally with Metox (**Fig. 8C, 8D**).

[0166] Mouse lungs and bone marrow were harvested and assayed by Real-Time PCR for the presence of human MicroNB cells. The metastatic load of MicroNB cells was significantly lower in lungs and bone marrow of mice treated with Metox compared to that found in organs derived from mice treated with scrambled-Metox (**Fig. 8E, 8F**).

**References**

- Aguirre-Ghiso, J.A. 2007. Models, mechanisms and clinical evidence for cancer dormancy. *Nat Rev Cancer* 7:834-846.
- Biedler, J.L., S. Roffler-Tarlov, M. Schachner, and L.S. Freedman. 1978. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. *Cancer Res* 38:3751-3757.
- Chambers, A.F., A.C. Groom, and I.C. MacDonald. 2002. Dissemination and growth of cancer cells in metastatic sites. *Nat Rev Cancer* 2:563-572.
- Cowie, F., R. Corbett, and C.R. Pinkerton. 1997. Lung involvement in neuroblastoma: incidence and characteristics. *Med Pediatr Oncol* 28:429-432.
- Edry Botzer, L., S. Maman, O. Sagi-Assif, T. Meshel, I. Nevo, T. Bauerle, I. Yron, and I.P. Witz. 2011. Lung-residing metastatic and dormant neuroblastoma cells. *Am J Pathol* 179:524-536.
- Gupta, G.P., and J. Massague. 2006. Cancer metastasis: building a framework. *Cell* 127:679-695.
- Holmgren, L., M.S. O'Reilly, and J. Folkman. 1995. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. *Nat Med* 1:149-153.
- Ishikawa, N., S. Ohlmeier, K. Salmenkivi, M. Myllarniemi, I. Rahman, W. Mazur, and V.L. Kinnula. 2010. Hemoglobin alpha and beta are ubiquitous in the human lung, decline in idiopathic pulmonary fibrosis but not in COPD. *Respiratory research* 11:123.
- Joyce, J.A., and J.W. Pollard. 2009. Microenvironmental regulation of metastasis. *Nat Rev Cancer* 9:239-252.
- Kim, Y., M.A. Stolarska, and H.G. Othmer. 2011. The role of the microenvironment in tumor growth and invasion. *Prog Biophys Mol Biol* 106:353-379.
- Klein-Goldberg, A., S. Maman, and I.P. Witz. 2014. The role played by the microenvironment in site-specific metastasis. *Cancer Lett* 352:54-58.
- Maman, S., L. Edry-Botzer, O. Sagi-Assif, T. Meshel, W. Yuan, W. Lu, and I.P. Witz. 2013. The metastatic microenvironment: lung-derived factors control the viability of neuroblastoma lung metastasis. *Int J Cancer* 133:2296-2306.
- Maman, S., and I.P. Witz. 2013b. The metastatic microenvironment. In *The Tumor Immunoenvironment*. M.R. Shurin, V. Umansky, and A. Malyguine, editors. Springer, N.Y, 745.
- Merrifield, R.B. 1963. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. *Journal of the American Chemical Society* 85:2149-2154.

- Nevo, I., O. Sagi-Assif, L. Edry Botzer, D. Amar, S. Maman, N. Kariv, L.E. Leider-Trejo, L. Savelyeva, M. Schwab, I. Yron, and I.P. Witz. 2008. Generation and characterization of novel local and metastatic human neuroblastoma variants. *Neoplasia* 10:816-827.
- Paez, D., M.J. Labonte, P. Bohanes, W. Zhang, L. Benhanim, Y. Ning, T. Wakatsuki, F. Loupakis, and H.J. Lenz. 2012. Cancer dormancy: a model of early dissemination and late cancer recurrence. *Clin Cancer Res* 18:645-653.
- Pantel, K., and C. Alix-Panabieres. 2007. The clinical significance of circulating tumor cells. *Nat Clin Pract Oncol* 4:62-63.
- Pantel, K., and R.H. Brakenhoff. 2004. Dissecting the metastatic cascade. *Nat Rev Cancer* 4:448-456.
- Pietsch, T., E. Gottert, E. Meese, N. Blin, H.J. Feickert, H. Riehm, and G. Kovacs. 1988. Characterization of a continuous cell line (MHH-NB-11) derived from advanced neuroblastoma. *Anticancer Res* 8:1329-1333.
- Rosenfeld, J., J. Capdevielle, J.C. Guillemot, and P. Ferrara. 1992. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. *Analytical biochemistry* 203:173-179.
- Schnolzer, M., P. Alewood, A. Jones, D. Alewood, and S.B. Kent. 1992. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. *International journal of peptide and protein research* 40:180-193.
- Smith, M.A., N.L. Seibel, S.F. Altekruse, L.A. Ries, D.L. Melbert, M. O'Leary, F.O. Smith, and G.H. Reaman. 2010. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. *J Clin Oncol* 28:2625-2634.
- Tomayko, M.M., and C.P. Reynolds. 1989. Determination of subcutaneous tumor size in athymic (nude) mice. *Cancer chemotherapy and pharmacology* 24:148-154.
- Townson, J.L., and A.F. Chambers. 2006. Dormancy of solitary metastatic cells. *Cell Cycle* 5:1744-1750.
- Wikman, H., R. Vessella, and K. Pantel. 2008. Cancer micrometastasis and tumour dormancy. *APMIS : acta pathologica, microbiologica, et immunologica Scandinavica* 116:754-770.
- Witz, I.P. 2008a. Tumor-microenvironment interactions: dangerous liaisons. *Adv Cancer Res* 100:203-229.
- Witz, I.P. 2008b. Yin-yang activities and vicious cycles in the tumor microenvironment. *Cancer Res* 68:9-13.

Witz, I.P., and O. Levy-Nissenbaum. 2006. The tumor microenvironment in the post-PAGET era. *Cancer letters* 242:1-10.

**WHAT IS CLAIMED IS:**


1. A method of screening a subject for micrometastases comprising (a) obtaining a biological sample from a subject, (b) determining the amount of an HBB peptide in the sample, and (c) comparing to amount determined in (b) with a reference amount.
2. The method of claim 1, wherein when the amount determined in (b) is more than the reference amount, the subject is diagnosed as having micrometastases.
3. The method of claim 1 or 2, wherein the biological sample is serum, blood or sputum.
4. The method of claim 1 or 2, wherein the HBB peptide is human hemoglobin beta subunit (HBB).
5. The method of claim 1 or 2, wherein the amount of an HBB peptide in the biological sample is determined by western blot, dot blot, slot blot, ELISA, RP-HPLC, LC-MS and LC-MS/MS.
6. A method of treating a subject having cancer comprising administering an effective amount of an HBB peptide to a subject having cancer.
7. The method of claim 6, wherein the cancer is selected from the group consisting of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and a cancer of the nervous system.
8. The method of claim 6 or 7, wherein the cancer is neuroblastoma.
9. The method of claim 6 or 7, wherein the HBB peptide comprises the amino acid sequence ENFRLLGNVLCVLA, termed HBB11p (SEQ ID NO:5).
10. A methods of inhibiting development of cancer in a subject at risk of developing cancer comprising administering an effective amount of an HBB peptide to a subject at risk of developing cancer.
11. The method of claim 10, wherein the cancer is selected from the group consisting of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and a cancer of the nervous system.
12. The method of claim 10 or 11, wherein the cancer is neuroblastoma.
13. The method of claim 10 or 11, wherein the HBB peptide comprises the amino acid sequence ENFRLLGNVLCVLA, termed HBB11p (SEQ ID NO:5).
14. The method of claim 10 or 11, wherein the subject at risk of developing cancer is a subject that was previously treated for cancer.

15. The method of claim 10 or 11, wherein the subject at risk of developing cancer is a subject in which cancer was previously cured.
16. A method of inhibiting metastasis of cancer in a subject having cancer comprising administering an effective amount of an HBB peptide to a subject having cancer.
17. The method of claim 16, wherein the cancer is selected from the group consisting of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and a cancer of the nervous system.
18. The method of claim 16 or 17, wherein the cancer is neuroblastoma.
19. The method of claim 16 or 17, wherein the HBB peptide comprises the amino acid sequence ENFRLLGNVLCVLA, termed HBB11p (SEQ ID NO:5).
20. A pharmaceutical composition comprising one or more HBB peptides and a pharmaceutically acceptable carrier.
21. The method of claim 20, wherein the HBB peptide comprises the amino acid sequence ENFRLLGNVLCVLA, termed HBB11p (SEQ ID NO:5).
22. Use of an HBB peptide in a method of treating a subject having cancer.
23. The use of claim 22, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.
24. The use of claim 22 or 23, wherein the cancer is neuroblastoma.
25. Use of an HBB peptide in a method of inhibiting development of cancer in a subject at risk of developing cancer.
26. The use of claim 25, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.
27. The use of claim 25 or 26, wherein the cancer is neuroblastoma.
28. The use of claim 25 or 26, wherein the subject at risk of developing cancer is a subject that was previously treated for cancer or neuroblastoma.
29. The use of claim 25 or 26, wherein the subject at risk of developing cancer is a subject in which cancer or neuroblastoma was previously cured.
30. Use of an HBB peptide in a method of inhibiting metastasis of cancer in a subject having cancer.


31. The use of claim 30, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.
32. The use of claim 30 or 31, wherein the cancer is neuroblastoma.
33. Use of an HBB peptide for the manufacture of a medicament for treating cancer in a subject.
34. The use of claim 33, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.
35. The use of claim 33 or 34, wherein the cancer is neuroblastoma.
36. Use of an HBB peptide for the manufacture of a medicament for inhibiting development of cancer in a subject at risk of developing cancer.
37. The use of claim 36, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.
38. The use of claim 36 or 37, wherein the cancer is neuroblastoma.
39. Use of an HBB peptide for the manufacture of a medicament for inhibiting metastasis of cancer in a subject having cancer.
40. The use of claim 39, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.
41. The use of claim 39 or 40, wherein the cancer is neuroblastoma.

Figure 1

A.



B.



C.





Figure 1

D.



E.





Figure 2

A.




B.

VHLTPEEKSAVTALWGKVVNVEVGGEALGRL  
 LVVYPWTQRFESFGDLSTPDVAVMGNPKVK  
 AHGKVKLGAFSDGLAHLNLIKGTFTLSELH  
 CDKLVDPENFRLLGNVLCVLAHFGKEFT  
 PPVQAAAYQKVVAGVANALAHKYH



Mouse hemoglobin subunit beta (HBB2)



C.






Figure 3

A.



B.



C.





Figure 3

D.



E.





Figure 4

A.



B.




Figure 4

C.





Figure 5

A.



B.




Figure 5





Figure 6

A.



B.





Figure 6

C.



D.





Figure 7

A.



B.





Figure 7

C.



D.




Figure 7

E.





Figure 8

A.



B.





Figure 8

C.



D.






Figure 8

E.



F.



**A. CLASSIFICATION OF SUBJECT MATTER**

**G01N 33/68(2006.01)i, G01N 33/53(2006.01)i, G01N 30/22(2006.01)i, G01N 30/72(2006.01)i, A61K 38/42(2006.01)i, A61P 35/00(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

G01N 33/68; A61K 38/08; A61K 38/17; G01N 33/53; G01N 30/22; G01N 30/72; A61K 38/42; A61P 35/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords: HBB, cancer, metastasis, neuroblastoma

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2013-074820 A1 (UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION) 23 May 2013 See abstract; pages 12-13; claims 1-47.	20-41
A	CAPULLI et al., 'Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs' Journal of Bone and Mineral Research, Vol.27, No.11, pp.2387-2398 (2012) See the whole document.	20-41
A	STRECKFUS et al., 'Salivary protein profiles among HER2/neu-receptor-positive and -negative breast cancer patients: Support for using salivary protein profiles for modeling breast cancer progression' Journal of Oncology, Vol.2012, Article ID.413256, pp.1-9 (2012) See the whole document.	20-41
A	LIU et al., 'Effect of chronic intermittent hypoxia on biological behavior and hypoxia-associated gene expression in lung cancer cells' Journal of Cellular Biochemistry, Vol.111, Issue No.3, pp.554-563 (2010) See the whole document.	20-41

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

05 August 2015 (05.08.2015)

Date of mailing of the international search report

**05 August 2015 (05.08.2015)**

Name and mailing address of the ISA/KR


International Application Division  
Korean Intellectual Property Office  
189 Cheongsu-ro, Seo-gu, Daejeon Metropolitan City, 302-701,  
Republic of Korea

Facsimile No. +82-42-472-7140

Authorized officer

KIM, Seung Beom

Telephone No. +82-42-481-3371



**INTERNATIONAL SEARCH REPORT**International application No.  
**PCT/US2015/031996**

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	MAMAN et al., 'A new lung-derived factor inhibits neuroblastoma lung metastasis by inducing cancer cell dormancy' In: 15th International Biennial Congress of the Metastasis Research Society, Heidelberg, Germany, page 181(B4) (30 June 2014) See the whole document.	20-41

**INTERNATIONAL SEARCH REPORT**International application No.  
**PCT/US2015/031996****Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 1-19  
because they relate to subject matter not required to be searched by this Authority, namely:  
Claims 1-19 pertain to methods for treatment of the human body by therapy or surgery, and thus relate to a subject matter which this International Searching Authority is not required, under PCT Article 17(2)(a)(i) and PCT Rule 39.1(iv), to search.
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2015/031996**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2013-074820 A1	23/05/2013	US 2014-0314758 A1	23/10/2014

专利名称(译)	使用血红蛋白β亚基治疗癌症和抑制转移		
公开(公告)号	<a href="#">EP3146344A1</a>	公开(公告)日	2017-03-29
申请号	EP2015795747	申请日	2015-05-21
[标]申请(专利权)人(译)	马里兰大学巴尔的摩分校 特拉维夫大学拉莫特有限公司		
申请(专利权)人(译)	马里兰州巴尔的摩大学 拉莫特AT特拉维夫大学LTD.		
当前申请(专利权)人(译)	马里兰州巴尔的摩大学 拉莫特AT特拉维夫大学LTD.		
[标]发明人	LU WUYUAN WITZ ISAAC MAMAN SHELLY		
发明人	LU, WUYUAN WITZ, ISAAC MAMAN, SHELLY		
IPC分类号	G01N33/68 G01N33/53 G01N30/22 G01N30/72 A61K38/42 A61P35/00		
CPC分类号	A61K38/16 A61K38/1709 A61K38/42 A61P35/00 A61K47/6445 G01N33/57488 G01N33/721 G01N2030/8813 A61K38/10 C12N5/0693 G01N30/22 G01N30/72 G01N30/88 G01N33/53 G01N33/68		
优先权	62/001911 2014-05-22 US 62/095413 2014-12-22 US		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

小鼠血红蛋白 ( HBB2 ) 的β2亚基已被鉴定为来自小鼠肺的可溶性因子 , 其对神经母细胞瘤肺微转移具有细胞抑制/细胞毒活性。已发现人血红蛋白 ( HBB ) 的β亚基具有相似的活性。提供了使用这些蛋白质及其片段治疗癌症和抑制转移的方法 , 以及通过检测生物样品中的HBB筛选受试者的微转移的方法。